Volume 2.10 | Mar 15

Hematopoiesis News 2.10, March 15, 2011.
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
 
TOP STORY
Prospective Separation of Normal and Leukemic Stem Cells Based on Differential Expression of TIM3, a Human Acute Myeloid Leukemia Stem Cell Marker
Scientists report the identification of TIM3 as an acute myeloid leukemia (AML) stem cell surface marker more highly expressed on multiple specimens of AML leukemia stem cells than on normal bone marrow hematopoietic stem cells. [Proc Natl Acad Sci U S A]

STEMvision_645x110_v01c.jpg
SPECIAL FEATURE
social_default_facebook_icon.jpg Cell Therapy News is now on Facebook! Join us.

social_default_twitter_icon.jpg Follow us on Twitter! @Hema_News

Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at
[email protected]
SCIENCE NEWS
Gene that Mediates Response to Key Cancer Drugs Frequently Mutated in Young Leukemia Patients Who Relapse
Investigators identified mutations in a gene named CREBBP that may help acute lymphoblastic leukemia (ALL) resist steroid treatment and fuel ALL’s return. [Press release from St. Jude Children’s Research Hospital discussing online prepublication in Nature]

ProficiencyTesting_v01_645x110-Video.jpg
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Enforced Expression of MLL-AF4 Fusion in Cord Blood CD34+ Cells Enhances the Hematopoietic Repopulating Cell Function and Clonogenic Potential but Is Not Sufficient to Initiate Leukemia
Here, researchers explored in vitro and in vivo the impact of the enforced expression of MLL-AF4 in human cord blood-derived CD34+ hematopoietic stem or progenitor cells. [Blood]

Structural Insights into the Extracellular Assembly of the Hematopoietic Flt3 Signaling Complex
Here, investigators reported the structural basis for the Flt3 ligand-receptor complex and unveiled an unanticipated extracellular assembly unlike any other class-III receptor tyrosine kinase/V complex characterized to date. [Blood]

Co-Expression of Tim-3 and PD-1 Identifies a CD8+ T-Cell Exhaustion Phenotype in Mice with Disseminated Acute Myelogenous Leukemia
Here scientists identified a unique phenotype of exhausted T-cells in mice with advanced acute myelogenous leukemia. [Blood]

Combined Characterization of MicroRNA and mRNA Profiles Delineates Early Differentiation Pathways of CD133+ and CD134+ Hematopoietic Stem and Progenitor Cells
To elucidate the role of microRNAs in the early steps of hematopoiesis, researchers directly compared donor-matched CD133+ cells with the more differentiated CD34+ CD133 and CD34 CD133 cells from bone marrow on the microRNA and mRNA level. [Stem Cells]

Cellular Aging Leads to Functional Heterogeneity of Hematopoietic Stem Cells – A Modeling Perspective
Investigators were able to conclude that division-dependent processes of cellular aging explain a wide range of phenomena on hematopoietic stem cells (HSC) exhaustion and that HSC aging needs to be considered as a highly heterogeneous process. [Aging Cell]

CD52 as a Molecular Target for Immunotherapy to Treat Acute Myeloid Leukemia with High EVI1 Expression
In this study, scientists determined that CD52 is highly expressed in most cases of acute myeloid leukemia with a high ecotropic viral integration site 1 (EVI1) expression. [Leukemia]

MicroRNA-193a Represses c-kit Expression and Functions as a Methylation-Silenced Tumor Suppressor in Acute Myeloid Leukemia
In this study, several microRNAs potentially binding to the 3′-untranslated region of human c-kit mRNA were screened by luciferase reporter assays. [Oncogene]

Human Adipose-Derived Stromal Cells Efficiently Support Hematopoiesis In Vitro and In Vivo: A Key Step for Therapeutic Studies
Researchers show that human adipose-derived stromal cells, cultured with GMP medium, maintain in vitro human early and committed hematopoietic progenitors and support their complete differentiation towards myeloid and lymphoid lineages. [Stem Cells Dev]

A New Allele of Lyl1 Confirms its Important Role in Hematopoietic Stem Cell Function
Data shows that in the absence of the HLH but presence of the N-terminus, residual function of the Lyl1 is detectable but relatively minor. [Genesis]

CLINICAL RESEARCH

CREBBP Mutations in Relapsed Acute Lymphoblastic Leukemia
To identify novel mutations in relapsed acute lymphoblastic leukemia (ALL), investigators resequenced 300 genes in matched diagnosis and relapse samples from 23 patients with ALL. [Nature]

Hematopoietic Stem Cell Transplantation Rates and Long-Term Survival in Acute Myeloid and Lymphoblastic Leukemia: Real-World Population-Based Data from the Swedish Acute Leukemia Registry 1997-2006
Scientists evaluated allogeneic stem cell transplantation rates within the Swedish Acute Leukemia Registry, including 3899 adult patients diagnosed from 1997 through 2006 with a coverage of 98% and a median follow-up of 6.2 years. [Cancer]

INDUSTRY NEWS
National Cord Blood Program Submits Biologics License Application
The National Cord Blood Program at New York Blood Center’s Howard P. Milstein National Cord Blood Center has submitted the first publicly-announced Biologics License Application for Cord Blood (Hematopoietic Progenitor Cells, Cord) to the U.S. Food and Drug Administration. [New York Blood Center Press Release]


Stemline Therapeutics Receives Orphan Drug Designation for SL-401 for the Treatment of Acute Myeloid Leukemia
Stemline Therapeutics, Inc. announced that SL-401 has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of acute myeloid leukemia. [Stemline Therapeutics, Inc. Press Release]

New Patent Issued for Talon Therapeutics’ Marqibo® Expands Disease Coverage to Include Lymphoma, Leukemia and Myeloma
Talon Therapeutics, Inc., announced the issuance of U.S. patent 7,887,836 B2, which covers compositions and methods for treating lymphoma, leukemia and myeloma for Marqibo (vincristine sulfate liposome injection). [Talon Therapeutics, Inc. Press Release]

ERYtech Pharma Announces Completion of Enrollment of a Phase II Clinical Trial for GRASPA® in First-Line for Elderly Patients with Acute Lymphoblastic Leukemia
ERYtech Pharma announced the early completion of the enrollment and safety follow-up a Phase II clinical trial for GRASPA®. [ERYtech Pharma® Press Release]

ERYtech Pharma to Present Promising Results for the Treatment of Sickle Cell Disease
ERYtech Pharma will in the near future present their promising results obtained with the GR-ARA1 project for the treatment of sickle cell disease. [ERYtech Pharma® Press Release]

$38.4 Million NHMRC Program Grants Extend Cancer and Blood Cell Research
Institute research into how cancer develops and blood cell production and function was awarded $38.4 million under the National Health and Medical Research Council’s (NHMRC) program grants scheme. [Walter and Eliza Institute of Medical Research Press Release]

OncoVista Innovative Therapies Outlines Business Strategy; “Company Is Moving Full-Speed Ahead,” Says CEO
OncoVista Innovative Therapies, Inc., reported in a letter to shareholders that it is moving forward on its business plan to develop targeted, safer and more efficacious cancer treatments with reduced or no toxicity. [OncoVista Innovative Therapies, Inc. Press Release]

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS
NEW BIT’s 4th Annual World Cancer Congress 2011
May 22-26, 2011
Dalian, China 

NEW
Molecular Diagnostics for Cancer Drug Development 
June 28-30, 2011 
Boston, United States

NEW
National Cancer Research Institute Cancer Conference 
November 6-9, 2011 
Liverpool, United Kingdom

Visit
our events page to see a complete list of events in the hematopoietic community.
JOB OPPORTUNITIES

Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Postdoctoral Research Scientist in Bone and Hematopoiesis (New York University)

Research Associate (University of Massachusetts Medical School)

Post-Doctoral Research Fellows – Transcriptional Control in Hematopoietic Stem Cells and Leukemia (Institut de Recherches Cliniques de Montréal) 

Research Technologist – Pharmaceutical Sciences (St. Jude Children’s Research Hospital)

Associate or Assistant Researcher (University of Wisconsin-Madison)

Investigator (The Children’s Hospital of Philadelphia and the University of Pennsylvania’s School of Medicine Academic)

Postdoctoral Fellow or Research Associate (City University of New York)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

Visit
here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us